Best Practices for Post-Approval Changes
1:15 p.m. - 2:30 p.m.
This Session will provide presentations on best practices for post-approval chemistry, manufacturing, and controls (CMC) and bioequivalence (BE) changes. Discussion and cases will include addressing areas needing guidance including post-approval changes to complex dosage forms such as Transdermal patches, MDI, DPI, and peptide drug products.
David Awotwe-Otoo, PhD
Senior Pharmaceutical Quality Assessor (SPQA), Division of Pharmaceutical Manufacturing Assessment II, OLDP, OPQ, CDER, FDA
CDR Lana Rossiter, PhD
Branch Chief, Division of Regulatory and Business Process Management III, OPRO, OPQ, FDA
Gina Sirianni, MSc
Director, Global Regulatory Affairs Co-Development, Apotex Inc.
Diana Vivian, PhD
Associate Director, Division of Bioequivalence II, OB, OGD, CDER, FDA
Vice President, North America Generic Regulatory Affairs, Teva Pharmaceuticals USA
CDR Andrew Fine, PharmD
Senior Advisor, Division of Clinical Review, OSCE, OGD, CDER, FDA
Hongling Zhang, PhD
Division Director, Division of Bioequivalence II, OB, OGD, CDER, FDA
Yan Wang, PhD
Team Leader, Division of Therapeutic Performance I, ORS, OGD, CDER, FDA